A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer Meeting Abstract
| Authors: | Melisi, D.; Hollebecque, A.; Oh, D. Y.; Calvo, E.; Varghese, A. M.; Borazanci, E. H.; Mercade, T. M.; Simionato, F.; Park, J. O.; Bendell, J. C.; Faivre, S. J.; Zhao, Y.; Gueorguieva, I.; Man, M.; Estrem, S.; Benhadji, K. A.; Lanasa, M.; Guba, S. C.; Garcia-Carbonero, R. |
| Abstract Title: | A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 252s |
| Language: | English |
| ACCESSION: | WOS:000487345805311 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.4124 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4124 -- Source: Wos |
